Arcutis Biotherapeutics (ARQT) closed at $23.92 on Oct 6, 2026, down 4.9% on the day. The stock is up 0.1% over the past month, down 16.1% over three months, down 17.6% year to date and up 20.1% over the past year. It trades 24.7% below its 52-week high of $31.77 and 24.0% above its 52-week low of $19.30. The close sits below its 50-day moving average ($25.57) and below its 200-day moving average ($25.17).
No — the Oct 6, 2026 close of $23.92 is 5.0% below the 200-day average of $25.17.
ARQT closed 24.7% below its 52-week high of $31.77.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
